Overview

Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock

Status:
Recruiting
Trial end date:
2023-12-02
Target enrollment:
0
Participant gender:
All
Summary
The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ain Shams University
Treatments:
Linezolid
Criteria
Inclusion Criteria:

- adult patients aged > 18 years old

- diagnosis of septic shock (patient with septic shock can be clinically identified by a
vasopressor requirement to maintain a mean arterial blood pressure of 65 mm Hg or
greater and serum lactate level greater than 2 mmol\L (>18 mg\dL) in the absence of
hypovolemia).

- positive culture confirming linezolid susceptibility.

Exclusion Criteria:

- Patient refusal.

- Known allergy to linezolid.

- Pregnancy and lactation.

- Severe hepatic failure (Child-Pugh C).

- Thrombocytopenia (platelet count < 80,000/mm3).

- Disseminated intravascular coagulation (DIC).

- Hematologic disease, and concurrent use of other medications that may interact with
linezolid (i.e., macrolides, serotonin modulators), or drug-associated
thrombocytopenia.